Opaganib
Phase 2Small molecule
Opaganib is one of 59 small molecule programs targeting Pneumonia. It is currently in Phase 2.
3
Indications
6
Total Trials
0
Active Trials
58
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1931 competitors in COVID-19
#DrugCompanyPhaseTrials
1Biaxin
AbbViePreclinical
Opaganib
RRedHill Biopharma Limited
Phase 2
Angiomax
BBaxter Healthcare Corporation
Preclinical
Tricor
JJagotec
Preclinical
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
Low-Molecular-Weight Heparin
Daiichi SankyoPreclinical
Statin
Bristol-Myers SquibbPreclinical
Blood Collection
AAssistance Publique - Hôpitaux de Paris
Preclinical
Exoflo
DDirect Biologics, LLC
Preclinical
Saliva Collection
DDirection Centrale du Service de Santé des Armées
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Pneumonia3 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Opaganib. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- RRedHill Biopharma Limited